Diabetogenic effects of cardioprotective drugs.
Diabetes Obes Metab
; 23(4): 877-885, 2021 04.
Article
em En
| MEDLINE
| ID: mdl-33319474
ABSTRACT
Drugs that protect against cardiovascular events in the patient with diabetes may also positively or negatively affect glycaemic control in the patient with established diabetes and may induce the development of diabetes in the predisposed patient. Mainly through increasing insulin resistance, beta-blockers, statins and high-dose diuretics have the potential to worsen glycaemic control. Dihydropyridine calcium channel blockers, low-dose diuretics, vasodilating beta-blockers, alpha-blockers and pitavastatin have little or no effect on glycaemic control. Blockers of the renin-angiotensin-aldosterone system, colesevelam, ranolazine and verapamil, through slowing breakdown of bradykinin, vasodilation, increasing cholecystokinin levels, blocking sodium channels and decreasing beta cell apoptosis, may improve glycaemic control and avoid the development of diabetes.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Preparações Farmacêuticas
/
Diabetes Mellitus
/
Hipertensão
Limite:
Humans
Idioma:
En
Revista:
Diabetes Obes Metab
Ano de publicação:
2021
Tipo de documento:
Article